NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Kairos Pharma's Participation in DealFlow Discovery Conference 2026
TL;DR
Kairos Pharma's investor presentation at the DealFlow Discovery Conference offers potential early insights into their oncology pipeline for competitive investment advantage.
Kairos Pharma will present clinical-stage oncology programs at the DealFlow Discovery Conference, detailing their structural biology approach to overcoming cancer drug resistance.
Kairos Pharma's clinical trials for ENV-105 aim to improve cancer treatment outcomes by addressing drug resistance and disease relapse in patients.
Kairos Pharma's lead candidate ENV-105 targets CD105 to reverse drug resistance in cancers like prostate and lung cancer during clinical trials.
Found this article helpful?
Share it with your network and spread the knowledge!
Kairos Pharma Ltd. (NYSE American: KAPA) announced it will participate in the DealFlow Discovery Conference on January 28–29, 2026, where Chief Scientific Officer Neil Bhowmick will deliver a company presentation and conduct one-on-one meetings with investors.
The conference will be held on January 28–29, 2026, at the Borgata Hotel, Casino & Spa in Atlantic City, New Jersey.
Chief Scientific Officer Neil Bhowmick will represent Kairos Pharma by delivering the company presentation and conducting one-on-one investor meetings during the event.
Kairos Pharma is focused on oncology therapeutics, using structural biology to address drug resistance and immune suppression in cancer. Its lead candidate is ENV-105, an antibody targeting CD105 to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.
ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, aimed at addressing significant unmet medical needs.
No, as of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA.
TinyGems is a specialized communications platform focused on innovative small-cap and mid-cap companies, part of the Dynamic Brand Portfolio @ IBN, which provides services like wire solutions, editorial syndication, press release enhancement, social media distribution, and tailored corporate communications solutions to help companies reach investors and the public.
This participation allows Kairos Pharma to engage with investors directly, showcasing its clinical-stage oncology programs and advancing its efforts to develop therapies for drug-resistant cancers, potentially enhancing investor awareness and support.
The full press release can be viewed at https://ibn.fm/0CBmk.
Curated from InvestorBrandNetwork (IBN)
